fbpx

molecules of the month

“Compound 19”

brain pen. UGT8 galactosyltransferase inh.

excellent oral PK/PD in brain model

from 30k cmpd cellular MTS and optimization

J. Med. Chem., Jun. 26, 2020

Sanofi R&D, Waltham, MA

Structure of compound 19
1 min read

“Compound 19” is a selective brain-penetrant inhibitor of the ceramide galactosyltransferase UGT8, intended for use in substrate reduction therapy for rare lysosomal storage disorders. The compound has good oral exposure in higher species (%F = 52 in dog) and is active in models looking at enzymatic activity using isotopically-labeled substrate. The molecule possesses a rare alkyl -OCF3 functional group, which appears to have improved potency vs. other small lipophilic groups.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: